PT Mitra Keluarga Karyasehat stock (ID1000135700): Removed from MSCI index in major rebalancing

PT Mitra Keluarga Karyasehat (MIKA) was removed from the MSCI Indonesia index following the latest rebalancing announced on May 13, 2026, amid changes in free float requirements and market adjustments.

PT Mitra Keluarga Karyasehat Tbk (MIKA), a leading Indonesian hospital operator, has been excluded from the MSCI Indonesia index as part of the global index provider's quarterly rebalancing effective May 13, 2026. This move affects 18 Indonesian stocks, including MIKA, due to updated free float ownership thresholds rising to 15% from 7.5%, according to CNN Indonesia as of 05/13/2026. The stock traded at 1,850 IDR on the Indonesia Stock Exchange (IDX), down 3.65% in the last 24 hours as of recent market data from TradingView as of 05/14/2026.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: PT Mitra Keluarga Karyasehat Tbk
• Sector/industry: Healthcare / Hospital Management
• Headquarters/country: Jakarta, Indonesia
• Core markets: Indonesia
• Key revenue drivers: Hospital services, patient care
• Home exchange/listing venue: Indonesia Stock Exchange (IDX: MIKA)
• Trading currency: IDR

PT Mitra Keluarga Karyasehat: core business model

PT Mitra Keluarga Karyasehat Tbk operates a network of hospitals across Indonesia, focusing on comprehensive healthcare services from primary care to specialized treatments. Founded in 1989 and headquartered in Jakarta, the company manages multiple facilities under the Mitra Keluarga brand, serving millions of patients annually. Its business model centers on high-quality medical services, efficient operations, and expansion through new hospital developments.

The firm reported net revenue of 4.87 trillion IDR for the full year (FY) period, with net income at 1.15 trillion IDR, according to data published on TradingView as of 05/14/2026. EBITDA stood at 1.99 trillion IDR with a 37.12% margin for the same period, reflecting strong operational profitability in the healthcare sector.

Main revenue and product drivers for PT Mitra Keluarga Karyasehat

Revenue is primarily driven by inpatient and outpatient services, diagnostics, and pharmacy operations within its hospital network. The company benefits from Indonesia's growing healthcare demand, fueled by population growth and rising middle-class spending on medical care. Recent quarterly net profit rose to 377.24 billion IDR from 328.76 billion IDR in the prior quarter, marking a 14.75% increase as reported on TradingView as of 05/14/2026.

Dividend payments are annual, with the latest at 43 IDR per share, yielding 1.70% trailing twelve months (TTM) and a payout ratio of 52.17% for 2024, per the same source. Market capitalization reached 35.84 trillion IDR recently, underscoring its position in the IDX healthcare space.

Industry trends and competitive position

Indonesia's healthcare sector is expanding rapidly, with hospital operators like PT Mitra Keluarga Karyasehat capitalizing on government initiatives for universal health coverage and private investments. The company holds a strong competitive edge through its established brand and extensive network, though it faces rivalry from state-owned and other private providers.

Why PT Mitra Keluarga Karyasehat matters for US investors

For US investors, PT Mitra Keluarga Karyasehat offers exposure to Southeast Asia's burgeoning healthcare market via American Depositary Receipts or global funds tracking IDX stocks. Its removal from MSCI indices may prompt portfolio adjustments by index-tracking ETFs, potentially impacting liquidity and visibility for international holders.

Conclusion

The exclusion of PT Mitra Keluarga Karyasehat from the MSCI index highlights ongoing adjustments in Indonesia's equity market amid stricter free float rules. With solid financials including rising quarterly profits and a stable dividend yield, the stock remains a key player in healthcare. Investors monitoring IDX developments will watch for post-rebalancing trading dynamics and any strategic responses from the company.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.